4 Analysts Have This to Say About Karyopharm Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Karyopharm Therapeutics (NASDAQ:KPTI) stock. The company has an average price target of $8.75, a decrease of 27.08% from the previous average price target of $12.00. The analysts' ratings are either bullish or somewhat bullish.
July 18, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have given bullish or somewhat bullish ratings to Karyopharm Therapeutics, with an average price target of $8.75, a decrease from the previous target.
The news is directly about Karyopharm Therapeutics and its stock ratings by analysts. The bullish ratings indicate a positive outlook, but the decrease in the average price target may cause some uncertainty among investors, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100